Vertex and Obsidian Therapeutics Establish New Collaboration

April 22, 2021
Pharmaceutical Executive Editorial Staff

Multi-year strategic research collaboration leverages Obsidian’s proprietary cytoDRiVE platform to discover controllable genetic therapies to treat serious diseases.

Vertex Pharmaceuticals Incorporated and Obsidian Therapeutics announced today that the two companies have entered into a strategic research collaboration and licensing agreement focused on the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The collaboration leverages Obsidian’s cytoDRiVE platform technology to discover gene-editing medicines whose therapeutic activity can be precisely controlled using small molecules and Vertex’s established scientific and clinical capabilities in small molecule, cell and genetic therapies to more rapidly bring these approaches to patients.

Under the terms of the agreement, Obsidian grants Vertex the exclusive option to license worldwide rights to candidates discovered and developed under the collaboration. Following Vertex’s exercise of its options, Vertex will be responsible for further preclinical and clinical development and commercialization.

For more information, click here.